Navigation Links
Based on Up to 6 Years of Follow-Up, Biovest Announces Favorable,Interim Blinded Data for Fast-Tracked Pivotal Phase 3 Clinical,Trial of BiovaxID Anti-Cancer Vaccine for Non-Hodgkin's Lymphoma

WORCESTER, Mass.--(BUSINESS WIRE)--Jun 28, 2007 - Biovest International, Inc. (OTCBB: BVTI), a majority owned subsidiary of Accentia Biopharmaceuticals, Inc. (NASDAQ:ABPI), announced on June 27, 2007 blinded interim data from the start of its fast-tracked pivotal Phase 3 clinical trial of BiovaxID(TM) for Non-Hodgkin's lymphoma (NHL) from September 2000 through June 2006. This interim blinded data is the most recent data that has been made available to the Company prior to its latest meeting with the Data Monitoring Committee for the ongoing Phase 3 study. The interim blinded data covers 122 patients who have received either BiovaxID or control vaccine. Randomization was 2:1 in favor of BiovaxID. The blinded data in a Kaplan Meier disease-free survival curve for the per-protocol treatment group in the trial showed that approximately 40% of the evaluable patients in the study remained disease-free from 40 months to almost 70 months.

Dr. Steve Arikian, Biovest Chairman and Chief Executive Officer, stated, "Biovest believes these results are consistent with the expected efficacy of BiovaxID vs. control. Moreover, BiovaxID has the longest Phase 3 follow-up data for patients receiving an active immunotherapy for follicular Non-Hodgkin's Lymphoma of any of the Phase 3 Non-Hodgkin's Lymphoma immunotherapy trials ongoing today. We are greatly encouraged by the blinded interim data presented at the Jeffries Healthcare Conference on June 27th, 2007."

BiovaxID is an anti-cancer vaccine undergoing testing in a Fast-Tracked pivotal Phase 3 clinical trial for a target indication of Non-Hodgkin's Lymphoma. BiovaxID is a personalized, patient-specific vaccine designed to stimulate the patient's own immune system to recognize and destroy residual cancerous B-cells that remain after the patient has undergone chemotherapy. Unlike many other approaches to treating NHL, BiovaxID is designed to target only cancerous B-cells.
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Pieris Progresses Proprietary Asthma Program: Validation of Pulmonary Delivery of Anticalin-Based Protein Product Candidate
2. Response Genetics Announces Publication of a Phase III Clinical Trial Demonstrating That Low Levels of ERCC-1 Help to Predict Likelihood of Response to Cisplatin-Based Therapy in Lung Cancer
3. Velcade (bortezomib) for Injection Based Induction Therapy Delivered High Post-Transplant Complete Remission Rate, a Critical Marker for Increased Overall Survival
4. Velcade (Bortezomib) for Injection Based Therapies Produced Complete Remission Rates as High as 54 Percent in Patients With Previously Treated Multiple Myeloma
5. Velcade (bortezomib) for Injection Based Therapies Achieved Survival Rates as High as 100 Percent in Newly Diagnosed Multiple Myeloma Patients
6. Research Documents Scalable Production, Survival Following Engraftment and Positive Impact on Cardiac Function in Infarcted Rats for Gerons Human Embryonic Stem Cell-Based Therapeutic for Heart Failure
7. Research Indicates Gerons Human Embryonic Stem Cell-Based Therapeutic for Spinal Cord Injury Evades Direct Attack by the Human Immune System
8. Celator Pharmaceuticals Study Shows Anti-Tumor Activity in Cancer Patients Treated with Therapy Based on Ratiometric Dosing
9. Eloxatin (oxaliplatin injection)-Based Chemotherapy Sets New Treatment Benchmark in Patients With Metastatic Colorectal Cancer
10. The Eloxatin-Based Regimen (FOLFOX4) Significantly Improved Progression Free Survival When Given Before and After Surgery in Patients With Resectable Liver Metastases From Colorectal Cancer
11. Othera Pharmaceuticals Announces Upcoming Presentation Based Upon Expanded Understanding of Lead Compound Mechanism of Action
Post Your Comments:
(Date:8/20/2014)... YORK , Aug. 20, 2014 ... new market research report is available ... Market for Hospital-Acquired Infection Control (Sterilization, ... http://www.reportlinker.com/p01618925/The-Market-for-Hospital-Acquired-Infection-Control-Sterilization-Disinfection-Testing-and-Treatment.html ... healthcare-associated infections (HAIs), demand has increased ...
(Date:8/20/2014)... NEW YORK , Aug. 20, 2014 ... market research report is available in its ... Insurance in Canada, Key Trends and Opportunities ... Synopsis The report ... insights into the Canadian personal accident and ...
(Date:8/20/2014)... Aug. 20, 2014 Research and ... "Global Biosimilars/Follow-on-Biologics Market (Technology, Types, Applications, Services ... report to their offering. ... applications and geography) - Size, Share, Global Trends, ... Segmentation and Forecast, 2013 - 2020", suggests that ...
Breaking Medicine Technology:The Market for Hospital-Acquired Infection Control (Sterilization, Disinfection, Testing and Treatment) 2The Market for Hospital-Acquired Infection Control (Sterilization, Disinfection, Testing and Treatment) 3The Market for Hospital-Acquired Infection Control (Sterilization, Disinfection, Testing and Treatment) 4The Market for Hospital-Acquired Infection Control (Sterilization, Disinfection, Testing and Treatment) 5The Market for Hospital-Acquired Infection Control (Sterilization, Disinfection, Testing and Treatment) 6Personal Accident and Health Insurance in Canada, Key Trends and Opportunities to 2017 2Personal Accident and Health Insurance in Canada, Key Trends and Opportunities to 2017 3Personal Accident and Health Insurance in Canada, Key Trends and Opportunities to 2017 4Personal Accident and Health Insurance in Canada, Key Trends and Opportunities to 2017 5Personal Accident and Health Insurance in Canada, Key Trends and Opportunities to 2017 6Personal Accident and Health Insurance in Canada, Key Trends and Opportunities to 2017 7Personal Accident and Health Insurance in Canada, Key Trends and Opportunities to 2017 8Personal Accident and Health Insurance in Canada, Key Trends and Opportunities to 2017 9Personal Accident and Health Insurance in Canada, Key Trends and Opportunities to 2017 10Personal Accident and Health Insurance in Canada, Key Trends and Opportunities to 2017 11Personal Accident and Health Insurance in Canada, Key Trends and Opportunities to 2017 12Personal Accident and Health Insurance in Canada, Key Trends and Opportunities to 2017 13Personal Accident and Health Insurance in Canada, Key Trends and Opportunities to 2017 14Personal Accident and Health Insurance in Canada, Key Trends and Opportunities to 2017 15Personal Accident and Health Insurance in Canada, Key Trends and Opportunities to 2017 16Personal Accident and Health Insurance in Canada, Key Trends and Opportunities to 2017 17Personal Accident and Health Insurance in Canada, Key Trends and Opportunities to 2017 18Personal Accident and Health Insurance in Canada, Key Trends and Opportunities to 2017 19Personal Accident and Health Insurance in Canada, Key Trends and Opportunities to 2017 20Personal Accident and Health Insurance in Canada, Key Trends and Opportunities to 2017 21Personal Accident and Health Insurance in Canada, Key Trends and Opportunities to 2017 22Personal Accident and Health Insurance in Canada, Key Trends and Opportunities to 2017 23Global Biosimilars/Follow-on-Biologics Market (Technology, Types, Applications, Services and Geography) - Research Report, 2013 - 2020 2
... May 21, 2012  Aushon announced its plans ... its new multiplex protein biomarker platform, which ... performance.  Aushon,s ultra-precise microarray printing, novel assay ... the sensitivity and reproducibility of single-plexed ELISA ...
... BOONTON, N.J., May 21, 2012   Unigene Laboratories, Inc. ... design, delivery, manufacture and development of peptide-based therapeutics, today ... Nozer Mehta, Ph.D., will be presenting at the TIDES ... held at the Mandalay Bay Resort and Casino in ...
Cached Medicine Technology:Aushon to Launch New Multiplex Immunoassay Platform 2Unigene to Present at TIDES 2012 2Unigene to Present at TIDES 2012 3
(Date:8/21/2014)... Relias Learning, the leader in SaaS-based training and ... announced the latest release of its flagship LMS with ... , “Supporting the Tin Can API ensures our ... learning capabilities and the ability to leverage the latest ... Jim Triandiflou, CEO of Relias Learning. “To provide our ...
(Date:8/21/2014)... ERT, a leading global ... efficacy endpoint data collection, today opened registration ... Maximizing Product Value with Optimized Endpoints. ... biopharmaceutical developers to network with leading researchers ... developing, implementing, and justifying effective strategies for ...
(Date:8/21/2014)... elicited by T-type calcium channels in the thalamic ... of calcium. These channels enable thalamic reticular nucleus ... to enter a hyper-excited state. , In order ... absence seizures, the researchers conducted an experiment to ... techniques to delete the T-type calcium channel CaV3.3. ...
(Date:8/21/2014)... we put on in the morning? Do we drive to ... we want to buy lunch? We make hundreds of different ... minimal impact, it is extremely important for our long-term personal ... People with ADHD often find this difficult, however. They are ... a prompt but smaller reward instead of making a choice ...
(Date:8/21/2014)... 21, 2014 The ... Vascular Devices Market by Angioplasty Balloon ... (IVUS, OCT), IVC Filter (Retrievable), Endovascular ... analyzes and studies the major market ... U.S. and Canada. , Browse 108 ...
Breaking Medicine News(10 mins):Health News:Relias Learning Announces Support for Tin Can API 2Health News:ERT Opens Registration for PROFICIENCY™ Regional Conference Series 2Health News:ERT Opens Registration for PROFICIENCY™ Regional Conference Series 3Health News:ADHD children make poor decisions due to less differentiated learning processes 2Health News:North American Interventional Cardiology and Peripheral Vascular Devices Market worth $5.9 Billion by 2018 - Research Report by MarketsandMarkets 2Health News:North American Interventional Cardiology and Peripheral Vascular Devices Market worth $5.9 Billion by 2018 - Research Report by MarketsandMarkets 3Health News:North American Interventional Cardiology and Peripheral Vascular Devices Market worth $5.9 Billion by 2018 - Research Report by MarketsandMarkets 4Health News:North American Interventional Cardiology and Peripheral Vascular Devices Market worth $5.9 Billion by 2018 - Research Report by MarketsandMarkets 5
... minister of Ireland has asked the health officials to review ... after an inquiry was probed in to the matter of ... killed by her mentally ill boyfriend Paul McCleery in March ... is a voluntary patient of mental health services provided by ...
... The case of an 11-year-old girl who is all set to ... shocked and frustrated health experts who maintain// that it is her ... whose identity is not being disclosed for legal reasons, is a ... pregnant after indulging in intercourse while on a drinking binge. The ...
... Madhya Pradesh has stated that more than 70 percent of ... of curriculum in schools//. ,The Madhya Pradesh Voluntary Health ... 10 to 19 years in 12 districts of the state. ... the awareness would help them remain healthy and not get ...
... a new study, oral and intravenous antiviral drug may ... ,Shingles, which is caused by varicella-zoster virus, is ... researchers at the University of Colorado and Health Sciences ... and three women with moderate to severe pain following ...
... been bitten by a bat and subsequently diagnosed with rabies has ... treatment is being offered, the chances of the boy recovering is ... student of Humble High School fell ill last week, unaware of ... this could happen, a bat had flown into his house while ...
... have been discovered by scientists at UCSF, Celera Genomics and ... risk// for early heart attack, or myocardial infarction (MI). ... a protein essential for early stages of clotting. When clotting ... heart attack. Knowing gene mutations that increase heart attack risk ...
Cached Medicine News:Health News:Health Experts Shocked As 11-year-old Girl To Be UK's Youngest Mother 2Health News:Girls In MP Want Sex Education In Schools: Health Survey 2Health News:Gene Variants Linked to Early Heart Attack Discovered 2Health News:Gene Variants Linked to Early Heart Attack Discovered 3Health News:Gene Variants Linked to Early Heart Attack Discovered 4
... helps provide protection to the exposed airway of ... lightweight making it ideal for active young children ... of heat and moisture recovery, it ensures patient ... and filters have ISO standard tapered ends to ...
For use with: , pulmonary function testing , nebulizer compressors , humidifiers , concentrators , proximal pressure lines ...
Indications For Usage: , ,For use during pulmonary lung function testing...
... The Portex® Thermovent® T helps provide protection ... It is small and extremely lightweight making it ... adults. With a high rate of heat and ... secretion retention., ,All HMEs and filters have ...
Medicine Products: